Premium
The duke afm program intensive induction chemotherapy for metastatic breast cancer
Author(s) -
Jones Roy B.,
Shpall Elizabeth J.,
Shogan Jeffrey,
Affronti Mary Lou,
Coniglio David,
Hart Lowell,
Halperin Edward,
Dirk Iglehart J.,
Moore Joseph,
Gockerman Jon,
Bast Robert C.,
Peters William P.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900801)66:3<431::aid-cncr2820660305>3.0.co;2-x
Subject(s) - medicine , folinic acid , regimen , chemotherapy , doxorubicin , breast cancer , metastatic breast cancer , methotrexate , toxicity , oncology , induction chemotherapy , fluorouracil , cancer , surgery
Abstract Forty‐five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5‐fluorouracil, and methotrexate with folinic acid rescue. This regimen was designed to produce rapid and extensive tumor shrinkage prior to high‐dose alkylating agent chemotherapy with autologous marrow support. The overall response rate was 91%, and 38% of patients achieved complete clinical responses after a mean of 70 days on treatment. Hematologic and mucosal toxicity were extensive, but no toxic deaths were noted. AFM is a potent remission induction regimen for metastatic breast cancer, but its considerable toxicity suggests caution in its use for routine breast cancer treatment.